ALKOGOLSIZ YOG'LI JIGAR KASALLIGI (AYJK): METABOLIK MEXANIZMLAR, TASHXISLASH VA ZAMONAVIY DAVOLASH YONDASHUVLARI
Keywords:
alkogolsiz yog'li jigar kasalligi, AYJK, alkogolsiz yog'li gepatit, AYJG, insulin rezistentligi, metabolik sindrom, jigar fibrozi, sirroz.Abstract
Alkogolsiz yog'li jigar kasalligi (AYJK) – alkogol iste'moli bilan bog'liq bo'lmagan holda gepatotsitlarda yog' to'planishi bilan kechadigan keng tarqalgan surunkali metabolik jigar patologiyasidir. Ushbu kasallik semizlik, insulin rezistentligi, 2-tip qandli diabet va metabolik sindrom bilan chambarchas bog'liq . AYJK spektri oddiy jigar yog'lanishidan boshlab, yallig'lanish va gepatotsitlar shikastlanishi bilan kechuvchi alkogolsiz yog'li gepatit (AYJG), rivojlangan fibroz va nihoyat sirrozigacha bo'lgan bosqichlarni o'z ichiga oladi . Kasallik patogenezida insulin rezistentligi, lipotoksiklik, oksidlovchi stress, mitoxondrial disfunksiya va proyallig'lanish sitokinlari muhim rol o'ynaydi . Erta diagnostika va xavf guruhlarini aniqlash kasallik progressiyasining oldini olishda hal qiluvchi ahamiyatga ega.
References
1. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. doi:10.1002/hep.28431
2. Estes C, Razavi H, Loomba R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123-133. doi:10.1002/hep.29466
3. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1 Suppl):S47-S64. doi:10.1016/j.jhep.2014.12.012
4. Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908-922. doi:10.1038/s41591-018-0104-9
5. Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184(10):2537-2564. doi:10.1016/j.cell.2021.04.015
6. Sheka AC, Adeyi O, Thompson J, et al. Nonalcoholic Steatohepatitis: A Review. JAMA. 2020;323(12):1175-1183. doi:10.1001/jama.2020.2298
7. Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017;14(1):32-42. doi:10.1038/nrgastro.2016.147
8. Samuel VT, Shulman GI. Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases. Cell Metab. 2018;27(1):22-41. doi:10.1016/j.cmet.2017.08.002
9. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology. 2010;52(2):774-788. doi:10.1002/hep.23719
10. Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol. 2017;14(7):397-411. doi:10.1038/nrgastro.2017.38
11. Schuster S, Cabrera D, Arrese M, Feldstein AE. Triggering and resolution of inflammation in NASH. Nat Rev Gastroenterol Hepatol. 2018;15(6):349-364. doi:10.1038/s41575-018-0009-6
12. Polyzos SA, Kountouras J, Mantzoros CS. Adipokines in nonalcoholic fatty liver disease. Metabolism. 2016;65(8):1062-1079. doi:10.1016/j.metabol.2015.11.006
13. Romeo S, Sanyal A, Valenti L. Leveraging Human Genetics to Identify Potential New Treatments for Fatty Liver Disease. Cell Metab. 2020;31(1):35-45. doi:10.1016/j.cmet.2019.12.002
14. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357. doi:10.1002/hep.29367
15. Castera L, Friedrich-Rust M, Loomba R. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2019;156(5):1264-1281. doi:10.1053/j.gastro.2018.12.036
16. Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. J Hepatol. 2018;68(2):305-315. doi:10.1016/j.jhep.2017.11.013
17. Nalbantoglu IL, Brunt EM. Role of liver biopsy in nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(27):9026-9037. doi:10.3748/wjg.v20.i27.9026
18. Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67(4):829-846. doi:10.1016/j.jhep.2017.05.016
19. Lassailly G, Caiazzo R, Ntandja-Wandji LC, et al. Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis. Gastroenterology. 2020;159(4):1290-1301. doi:10.1053/j.gastro.2020.06.006
20. Dufour JF, Caussy C, Loomba R. Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges. Gut. 2020;69(10):1877-1884. doi:10.1136/gutjnl-2019-319104
21. Cusi K, Orsak B, Bril F, et al. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. Ann Intern Med. 2016;165(5):305-315. doi:10.7326/M15-1774
22. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675-1685. doi:10.1056/NEJMoa0907929
23. Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679-690. doi:10.1016/S0140-6736(15)00803-X
24. Younossi ZM, Ratziu V, Loomba R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394(10215):2184-2196. doi:10.1016/S0140-6736(19)33041-7
25. Harrison SA, Wong VW, Okanoue T, et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. J Hepatol. 2020;73(1):26-39. doi:10.1016/j.jhep.2020.02.027
26. Karimov Sh.I., Axmedov R.A. Metabolik kasalliklarning jigar ko'rinishlari. Toshkent: Abu Ali ibn Sino nomidagi tibbiyot nashriyoti; 2019. 290 b.
27. Saidov M.S., Rahimov B.T. Ichki kasalliklar: Jigar va metabolik buzilishlar. Toshkent: Yangi Asr Avlodi; 2021. 375 b.
28. Yo'ldoshev A.A., Tursunov F.F. Alkogolsiz yog'li jigar kasalligi: metabolik mexanizmlar va klinik boshqaruv. Tibbiyot va Zamon. 2022;4(55):22-30.
29. Xalmatova B.T., Nishonov A.A. Semizlik va metabolik sindrom fonida AYJK rivojlanish xususiyatlari. O'zbekiston terapiya axborotnomasi. 2023;2(67):45-51.
30. Raximova D.X., Turg'unov X.X. Alkogolsiz yog'li jigar kasalligida invaziv bo'lmagan diagnostika usullarining qiyosiy tahlili. O'zbekiston tibbiyot jurnali. 2024;1(89):78-84.
